Table 3.
Frequencies of IL-17A and IFN-γ responders a against dmLT, LTB and CF antigens in ETEC infected patients.
| Day 2 | Day 7 | P-value b | Day 30 | P-value b | Day 90 | P-value b | Cumulative (Day 2/7/30/90) |
|
|---|---|---|---|---|---|---|---|---|
| IL-17A | ||||||||
| dmLT | 3/23 (13%) | 9/22 (41%) | 0.047 | 4/18 (22%) | 0.679 | 2/16 (13%) | 1.000 | 13/23 (56%) |
| LTB | 2/22 (9%) | 7/21 (33%) | 0.069 | 3/18 (17%) | 0.642 | 1/16 (6%) | 1.000 | 10/22 (45%) |
| CS6 | – | 3/10 (30%) | – | 2/9 (22%) | – | 1/7 (14%) | – | 5/10 (50%) |
| CS5 | – | 3/7 (43%) | – | 0/6 (0%) | – | 0/4 (0%) | – | 3/7 (43%) |
| CFA/I | – | 0/5 (0%) | – | 1/3 (33%) | – | 0/4 (0%) | – | 1/5 (20%) |
| IFN-γ | ||||||||
| dmLT | 1/23 (4%) | 8/22 (36%) | 0.010 | 5/18 (28%) | 0.070 | 3/16 (19%) | 0.286 | 10/23 (43%) |
| LTB | 1/22 (5%) | 1/21 (5%) | 1.000 | 3/18 (17%) | 0.310 | 1/16 (6%) | 1.000 | 4/22 (18%) |
| CS6 | – | 0/10 (0%) | – | 0/9 (0%) | – | 0/7 (0%) | – | 0/10 (0%) |
| CS5 | – | 0/7 (0%) | – | 0/6 (0%) | – | 0/4 (0%) | – | 0/7 (0%) |
| CFA/I | – | 0/5 (0%) | – | 1/3 (33%) | – | 0/4 (0%) | – | 1/5 (20%) |
a
A responder was defined as having ≥2-fold higher cytokine response compared to the mean+2SD cytokine concentration of the group of healthy controls.
b
Statistical analysis was performed using the Fisher’s Exact test to compare the responder frequency between day 7, 30 and 90 vs day 2, when day 2 samples were available (stimulation with dmLT and LTB).